

Remarks

In the Advisory Action mailed May 11, 2007, the Examiner states that the Amendment filed March 21, 2007 does not place the application in condition for allowance because claim 1 does not exclude synthetic polymers. The Examiner states that Bernstein teaches the use of synthetic polymers and that Applicants have shown adverse findings relating to the use of synthetic polymers. The present specification teaches away from the use of synthetic polymers in particles by presenting the negative consequences of administering a drug via microparticles comprising a synthetic polymer. Therefore, as suggested by the Examiner, Applicant has amended claims 1, 62, 63, 85, 86, and 90 to exclude synthetic polymers. No new matter has been added by the present Amendment. Support for this Amendment can be found in the specification on page 52 in sections entitled “Tissue reaction two weeks after injection” and “Tissue reaction eight weeks after injection” and on page 54 in the section entitled “*Other findings on dissection.*”

In view of the forgoing amendments and arguments, Applicant respectfully submits that the present case is now in condition for allowance. A Notice to that effect is requested.

If, at any time, it appears that a phone discussion would be helpful, the undersigned would greatly appreciate the opportunity to discuss such issues at the Examiner’s convenience. The undersigned can be contacted at (617) 248-5215.

Respectfully submitted,

/C. Hunter Baker/

C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

Choate, Hall & Stewart LLP
Two International Place
Boston, MA 02110
t (617) 248-5215
f (617) 248-4000
cbaker@choate.com
Date: June 20, 2007